Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.46 |
| ▸ | FLT3 | P36888 | 6/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 2/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336262 | 0.93 | FLT3 (0.46) | CDK2FLT3CCNA1CDK4CCND1 | |
| SCHEMBL6336261 | 0.93 | FLT3 (0.46) | CDK2FLT3CCNA1CDK4CCND1 | |
| SCHEMBL27574761 | 0.82 | HTR2C (0.45) | CDK2FLT3CCNA1CDK6HTR2C | |
| SCHEMBL6332705 | 0.81 | KMT2A (0.43) | CDK2FLT3CCNA1HTR2CMEN1 | |
| SCHEMBL6332707 | 0.81 | KMT2A (0.43) | CDK2FLT3CCNA1HTR2CMEN1 | |
| SCHEMBL27572764 | 0.80 | HTR2C (0.37) | CDK2FLT3CCNA1KDRHTR2C | |
| SCHEMBL6336973 | 0.80 | CDK2 (0.41) | CDK2FLT3CCNA1CDK4CCND1 | |
| SCHEMBL6334344 | 0.79 | HRH3 (0.38) | KDRHTR2CNR2F2 | |
| SCHEMBL6334345 | 0.79 | HRH3 (0.38) | KDRHTR2CNR2F2 | |
| SCHEMBL6500012 | 0.78 | MEN1 (0.39) | CDK2FLT3CCNA1HTR2CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | CDK2 719/4885FLT3 803/4885CCNA1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.